BRISBANE, Calif., April 25, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2011 financial results prior to the open of the U.S. markets on Thursday, April 28, 2011. A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day.
To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 62213806. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 62213806.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease. The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
SOURCE InterMune, Inc.